Home > Resources > Whitepapers > MicroRNA Expression Patterns Responsible for Inducing Chemo-Resistance in Ovarian Cancer

MicroRNA Expression Patterns Responsible for Inducing Chemo-Resistance in Ovarian Cancer

November 15, 2018

Despite significant progress in our understanding of the pathophysiology of cancer as a whole, ovarian cancer still remains as one of the most intractable forms of the disease with only 30% cure rate with the conventional therapy. It is also one of most common gynecologic cancer among women. One histologic variety is the epithelial ovarian cancer that constitutes more than 90% of the cases; also develop resistance to chemotherapeutic agents.

Spotlight

IPRO

IPRO is a national organization providing a full spectrum of healthcare assessment and improvement services that foster more efficient use of resources and enhance healthcare quality to achieve better patient outcomes. Founded in 1984, IPRO is highly regarded for the independence of its approach, the depth of its knowledge and experience, and the integrity of its programs. IPRO holds contracts with federal, state and local government agencies, as well as private-sector clients, in more than 33 states and the District of Columbia. A national not-for-profit organization, IPRO is headquartered in Lake Success, NY and has regional offices in Albany, NY, New Jersey, North Carolina, Connecticut.

OTHER WHITEPAPERS

How advanced purification technologies are speeding the hunt for new protections against disease

whitePaper | November 24, 2022

Smallpox was the first infectious disease for which an effective vaccine was developed. In the late 1700s, British doctor Edward Jenner devised a method to inoculate people with cowpox pus to give them immunity against smallpox, a much more deadly disease.

Harnessing the power of the human microbiome

whitePaper | January 20, 2023

We provide an overview of the human microbiome market, the observed challenges, how to overcome them and introduce future opportunities for pharmaceutical.

Bispecific Antibodies Unleashed from Mechanisms to Manufacturing and Strategic Collaboration for Effective Precision Immunotherapy

whitePaper | July 13, 2023

Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising therapeutic potential such that their applicability to a variety of therapies is being explored.

U.S. Biopharma Expansions to Europe: Ensuring Successful Build-Out & Market Access

whitePaper | May 24, 2023

The Greater Zurich Area Ltd (GZA), Apellis, and Korn Ferry co-hosted a virtual roundtable for a select group of biopharma leaders interested in expanding their operations into Europe. The panel brought together European launch specialists, talent experts, and Swiss government officials to cover critical questions and guiding principles necessary for a successful European launch, as well as insider knowledge of how to best navigate the regulatory environment.

Three Trends to Watch in Life Sciences

whitePaper | June 10, 2022

Healthcare is changing rapidly. Companies who provide products and services to hospitals and physicians will need to adjust their operations to change.

Validation of ICON™ Automated Cell Counting and Viability Assay

whitePaper | August 10, 2022

Determination of cell viability and concentration using trypan blue exclusion is essential for biotherapeutic workflows, enabling optimisation of protocols, monitoring of changes to the culture environment, and selection of the best clones for culture progression.